A calm, supportive guide for patients living with Allergic Bronchopulmonary Aspergillosis (ABPA)
Allergic Bronchopulmonary Aspergillosis (ABPA) can be confusing.
Some people hear “fungus” and think it is a dangerous infection.
Others hear “allergy” and think it has nothing to do with fungi at all.
The truth is somewhere in the middle — and understanding this can make your treatment feel much clearer and less frightening.
This article explains:
-
Whether ABPA is an infection, an allergy, or both
-
How the fungus Aspergillus fumigatus fits into the picture
-
Why biologics help — and whether they allow the fungus to grow
-
Why your future with ABPA is more hopeful than ever
🌼 1. Is ABPA an infection or an allergic over-reaction?
The simplest explanation is:
ABPA happens when Aspergillus lives in mucus in the airways, and the immune system overreacts. It’s driven by allergy, not by fungal invasion.
In ABPA:
-
Aspergillus fumigatus sits in mucus, especially in asthma, bronchiectasis or cystic fibrosis
-
It does not invade or damage lung tissue
-
The immune system becomes over-sensitised and reacts too strongly
This allergic reaction triggers:
-
Very high IgE
-
High eosinophils
-
Swelling, tightness, wheeze
-
Thick “stringy” mucus or plugs
-
Repeated flare-ups that feel like chest infections
The inflammation — not the fungus — is what damages the lungs over time.
🌻 2. If it’s not a typical infection, why treat the fungus?
Even though ABPA is allergic, reducing fungal load can still help.
Here’s why:
-
Less fungus in mucus → less allergen
-
Less allergen → less immune reaction
-
Less reaction → fewer flare-ups, better breathing
This is why some people take antifungals.
But antifungals are not always necessary, especially today with the arrival of biologics.
🌈 3. Do biologics weaken the immune system and let the fungus grow?
No.
This is a very common worry — but the biologics used for ABPA do not suppress the parts of the immune system that keep you safe from fungi.
Biologics such as:
-
Omalizumab (anti-IgE)
-
Mepolizumab / Benralizumab (anti-IL-5)
-
Dupilumab (anti-IL-4/IL-13)
-
Tezepelumab (anti-TSLP)
target overactive allergic pathways, not antifungal defences.
They do not affect:
-
Neutrophils
-
Macrophages
-
Dectin-1
-
TLR antifungal pathways
-
Complement
These are the real fungus-clearing systems — and biologics leave them intact.
🍃 4. Do biologics actually help clear fungus? Surprisingly, sometimes yes.
Many patients on biologics show:
-
Fewer mucus plugs
-
Better airflow
-
Fewer positive sputum cultures
-
Reduced symptoms
-
Lower exacerbation rates
-
Less need for steroids or antifungals
When mucus plugs shrink, fungus loses its hiding place.
Your natural defences can finally clear it.
So biologics do not encourage growth — they may even help reduce fungal load.
🌺 5. Why are outcomes improving so much?
ABPA used to be a condition dominated by:
-
frequent flare-ups
-
repeated steroids
-
fear of lung damage
-
long periods of being unwell
Today, with biologics:
-
far fewer flare-ups
-
easier breathing
-
more stable lung function
-
much less steroid use
-
better quality of life
-
higher confidence and control
For many patients, biologics are transforming ABPA from a cycle of crises into a more manageable long-term condition.
🌼 6. Key reassurance
If you remember only one sentence, let it be this:
Biologics calm the allergic response that causes ABPA, without weakening your natural ability to clear fungus — and many patients do better than ever on them.
🌟 7. Moving forward with confidence
ABPA is complex, but it is treatable, manageable, and increasingly well-understood.
You are not dealing with a dangerous lung infection — you are dealing with an over-active immune response that modern treatments can control.
With the right support, airway clearance, the best inhalers, and (where needed) biologics or antifungals, most people:
-
stabilise
-
breathe more easily
-
reduce flare-ups
-
protect their lungs
-
live full, active lives
You’re not alone — and the future for ABPA care has never looked brighter.
Latest News posts
News archive